GAITHERSBURG, Md., Jan 22 /PRNewswire-FirstCall/ -- Iomai Corporation announced that its Chief Scientific Officer, Gregory Glenn, M.D., will speak today at the Phacilitate Vaccine Forum Baltimore 2007. Dr. Glenn’s presentation is titled “Dose Sparing, Enhanced Immunogenicity and Mass Immunization Strategies for Pandemic Influenza Vaccines Using a Patch.”
The presentation will take place at 4:55 p.m. EST, during a pre-conference workshop, “Harnessing Novel Influenza Vaccine Manufacturing Technologies to Address Global Shortages: Making the Business Case for Building Capacity with New Technology.” The conference is being held at the Baltimore Marriott Waterfront.
Last week, Iomai announced that it had won a government contract to develop a dose-sparing patch for use with a pandemic influenza vaccine. If the product is developed through licensure, the total contract is estimated to be $128 million, with $14.5 million allocated for the first 15 months.
Dr. Glenn, the founder of Iomai, developed the company’s proprietary TCI (transcutaneous immunization technology) technology. TCI serves as the basis for the dose-sparing vaccine patch and the pipeline of other products that Iomai is developing, including a seasonal influenza vaccine and a vaccine for travelers’ diarrhea. The needle-free technology uses a patch placed on the surface of the skin to deliver vaccines and adjuvants via a group of antigen-presenting cells in the skin to the nearby lymph nodes, where a sustained immune response is triggered.
ABOUT IOMAI CORPORATION
Iomai Corporation discovers and develops vaccines and immune system stimulants, delivered via a novel, needle-free technology called transcutaneous immunization (TCI). TCI taps into the unique benefits of a major group of antigen-presenting cells found in the outer layers of the skin (Langerhans cells) to generate an enhanced immune response. Iomai is leveraging TCI to enhance the efficacy of existing vaccines, develop new vaccines that are viable only through transcutaneous administration and expand the global vaccine market. Iomai currently has four product candidates in development: three targeting influenza and pandemic flu and one to prevent E. coli-related travelers’ diarrhea. For more information on Iomai, please visit www.iomai.com .
Iomai Corporation
CONTACT: Russell P. Wilson, Senior Vice President, Chief Financial Officerand General Counsel of Iomai Corporation, +1-301-556-4478, orinvestors@iomai.com; or Brian Reid of WeissComm Partners, Inc.,+1-703-402-3626, or breid@weisscommpartners.com, for Iomai Corporation
Web site: http://www.iomai.com//
